Size: | Price | Quantity | |
---|---|---|---|
5 mg | $75.00 | ||
25 mg | $250.00 |
GRL-0617 (1093070-16-6) is a potent (IC50 = 600 nM) noncovalent inhibitor of severe acute respiratory syndrome-coronavirus papain-like protease (SARS-CoV PLpro). GRL-0617 inhibited SARS-CoV viral replication in Vero E6 cells with no cytotoxicity (EC50 = 15 µM). Inactive against human DUB-like proteases HAUSP, USP18, UCH-L1, UCH-L3, and PLP2
References/Citations
1) Ratia et al. (2008), A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication; Proc. Natl. Acad. Sci. USA, 105 16119
2) Ghosh et al. (2009), Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome-Coronavirus Papain-Like Protease; J. Med. Chem. 52 5228
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
GRL-0617 (1093070-16-6) is a potent (IC50 = 600 nM) noncovalent inhibitor of severe acute respiratory syndrome-coronavirus papain-like protease (SARS-CoV PLpro). GRL-0617 inhibited SARS-CoV viral replication in Vero E6 cells with no cytotoxicity (EC50 = 15 µM). Inactive against human DUB-like proteases HAUSP, USP18, UCH-L1, UCH-L3, and PLP2
References/Citations
1) Ratia et al. (2008), A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication; Proc. Natl. Acad. Sci. USA, 105 16119
2) Ghosh et al. (2009), Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome-Coronavirus Papain-Like Protease; J. Med. Chem. 52 5228
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.